

ATTACHMENT 1

SUBSTITUTE SPECIFICATION

Application No. : 10/689,450
Applicant : LEE, *et al.*
Filed : OCTOBER 20, 2003
Title : **DENSITY/SOLUTE MONITOR OF MULTI-MODALITIES AND
SIGNAL PROCESSING SCHEME**

Art Unit : 3737
Examiner : JAWORSKI, FRANCIS J.

Atty Docket No. : JLEE-0001-CP2 (FORMERLY GC-523)



Density/Solute Monitor of Multi-modalities and Signal Processing Scheme

This application is a continuation-in-part of U. S. Patent No. 6,740,036, filed October 18, 2002 and issued on May 25, 2004, which claims the priority of U. S. Patent 6,485,427 B1, filed July 18, 2001 and issued on November 26, 2002, and U.S. Provisional Application 60/218,906, filed July 18, 2000.

Field of the Invention

This invention generally relates to a device and method for monitoring fluid properties, and specifically relates to a density/solute monitor having ultrasound probes for continuous monitoring of the ultrasound velocity of fluid in a biological or chemical processing system in order to determine fluid density, compressibility, solute concentration, and the fluid flow and a method for using the same wherein the probes are integrated with modality measurements such as optical absorbance, conductivity, impedance, magnetic resonance, radiation attenuation, and tracers of fluid.

Background

Two classical methods of measuring density of a fluid include: 1) measuring the weight of fluid in a flask of fixed volume; and 2) employing the buoyancy of a density float for the assessment of fluid density. Both of these methods require collection of large samples from a fluid-processing device such as a pipeline or reactor for off-line measurements. For a given solution, density relates to the solute concentration of the solution. Although the density measurement is not specific to what solute is in the solution, these two density measurement

1 methodologies and others to be described later have been used as a means to assess solute
2 concentration.

3 A mechanical device based on resonance has been available to measure density of a fluid
4 sample or that of a flowing fluid on-line. The device has a hollow U-tube with its two ends
5 fixed on a heavy base. The fluid can be infused to fill the U-tube or made to flow along the tube.
6 By measuring the frequency that the U-tube resonates, one then determines the mass of fluid in
7 the U-tube. Since its volume is fixed, the mass is converted to the fluid density. This
8 mechanical density measuring system (MDMS) has high sensitivity and reproducibility in the
9 dynamic measurement of fluid density.

10 As a fourth density measurement method, one measures the sound velocity of fluid for
11 the determination of the compressibility and density of fluid. Krivitski, in U.S. Patent Numbers
12 5,453,576 and 5,685,989 describes an apparatus and method for measuring several hemodynamic
13 parameters by using a sound velocity sensor. The ultrasound transducer is excited to emit a pulse
14 of ultrasound. After its passage through a fluid medium such as the blood, a receiving transducer
15 senses the ultrasound pulse. A protocol to compare the excitation and receiving ultrasound
16 signals determines the transmission time through the blood and subsequently its sound velocity.
17 The information contained in the '576 and the '989 patent is incorporated by reference as though
18 cited in its entirety. When their device is used to measure blood density change for the
19 computation of blood volume, a linear approximation of a non-linear relationship is employed to
20 convert the sound velocity to the density of the blood. Furthermore, the device of the '576 patent
21 has limited sensitivity so as to require the imposition of a large change in blood density for
22 accurate assessment of blood volume.

The system patented by Schneditz in US Patent 5,830,365 also utilizes sound velocity for the measurement of transmission time delay through the blood and then its total protein concentration. A clinical protocol to change the ultrafiltration rate as a patient undergoing hemodialysis treatment is described to produce the change in density, which is assessed through a sound velocity monitor. An equation is deduced to compute from the change measurement the blood volume circulating in the patient. The monitor to measure density is about one order of magnitude less sensitive than that provided by the MDMS or our density/solute monitor. As a result, the application of Schneditz's method to measure blood volume is limited to cases that the change in sound velocity being imposed through the clinical protocol is large.

The fifth density measurement method employs the attenuation due to the absorption of radioactivity by the fluid as a means to assess its density. Approval by regulatory agency is required for this method.

Summary of the Invention

The present invention is directed to a density/solute monitor including an ultrasound probe and a signal processing unit for accurately and reliably determining the phase shift of ultrasound transmission through a fluid and then the sound velocity of the fluid and a method of applying the same to biological or chemical processing systems. A set of equations and measurements by other modalities are incorporated to deduce from the sound velocity the compressibility, density, concentration of specific solute, and concentration of particulate matters of the fluid. The monitor can be used to determine the mass flow of solute, to improve the performance of chemical processes, and to optimize process design. The improvement and optimization can lead to more efficient collection of solutes, more solute purity in the collection, and better efficiency of the chemical processes.

1 The novel embodiments of the density/solute monitoring system include a signal
2 processing unit with simple hardware and software to determine at high accuracy phase shift and
3 transmission time of ultrasound signals; a two-fluid calibration procedure to convert the phase
4 shift and transmission time in terms of sound velocity; an appropriate placement of the probe to
5 time the passage of certain solute injected upstream of the probe; the use of two probes in series
6 to measure volume flow; a procedure to work with the MDMS for the establishment of an
7 empirical relation between the density and sound velocity of fluid and to account for the
8 dependence on temperature; the calculation of the compressibility of the fluid to derive its
9 relation with the sound velocity and density of the fluid; a set of computer files and equations
10 specific to given solute, solution and density/solute monitor on the conversion of density to the
11 solute concentration in the solution.

12 The ultrasound probe can work alone or in combination with other detection modalities to
13 achieve more functionality for the density/solute monitor. Other detection modalities include:

14 (1) The use of optical absorbance and/or reflectance of light at frequency ranging from
15 infrared to ultraviolet, impedance and conductivity of microwave, and absorbance of
16 radiation for better identification of the solute of interest;

17 (2) A procedure using the injection of certain solution and the sensitivity of the
18 ultrasound probe to calibrate and determine the sensitivity of other detection
19 modalities;

20 (3) A procedure to detect the movement of tracers for system characterization.

21 The use of these embodiments will enable one to achieve at least one of the following features:

22 (1) A multi-functional detection system of low cost;

23 (2) Accurate assessments on the flow and passage of specific solute;

1 (3) Efficiency in the collection and purification of specific solute with the technology of
2 chromatography;

3 (4) Crucial information for industrial engineers to optimize the process design;

4 (5) Information for diagnosis and prevention of cardiac deficiencies in patients.

5 By making use of the high sensitivity of the ultrasound probe, the multi-modality monitor
6 gains additional power to determine the concentration of specific solute in the solution, the
7 passage of specific solute through a chromatography column, and the dynamic changes of the
8 solute in chemical or biological processing systems. In applying these probes and methods to
9 paper, petroleum, chemical, pharmaceutical, food and bioprocessing industry; the engineers can
10 determine more accurately the mass flow being transported through pipeline, achieve better
11 solute purity in solution collected from chromatography column, and control more responsively
12 the chemical or biological processing. The multi-modality methodology is applicable to human
13 for determinations of blood parameters, vascular functions, and cardiac performance. The
14 information provides key measurements for physicians to maintain homeostasis of the patient
15 and to diagnose or to prevent cardiac deficiencies such as hypotension and shock in patients
16 undergoing hemodialysis treatment or subject to trauma or burns.

17 Multi-modality probes and methods are described:

- 18 1. To monitor the phase shift between the emitting and receiving ultrasound and the
19 time of sound transmission in the fluid in pipelines or reactors;
- 20 2. To use a set of relationships and procedures to convert these phase and time
21 measurements into accurate assessment of sound velocity, density, compressibility,
22 solute concentration, and their changes;

3. To monitor a number of fluid properties in optical absorbance, reflectance, conductivity, impedance, magnetic resonance, radioactivity attenuation, and tracers to better specify the solute being assessed and to better time the flow and passage of the solute;
4. To employ these assessments for more efficient operation and control of chemical, physical and biological process common to chemical, pharmaceutical, food product, paper, and petroleum industries;
5. To improve the probes and algorithm for use as blood volume monitor claimed in U.S Patent numbers 6,740,036 and 6,485,427 B1.

Brief Description of the Drawings

Figure 1 is a schematic drawing of an embodiment of the ultrasound probe in the insertion mode. It has a pair of ultrasound transducers and a thermistor. The probe is inserted into a pipeline or reactor for measurements of fluid inside. In this design, the transducers and thermistor are in direct contact with the fluid.

Figure 2 is a schematic drawing of an embodiment of the ultrasound probe in the clip-on mode. It has a pair of ultrasound transducers and a thermistor. The probe is clipped on to a tube or column with flowing solution. In this design, the transducers and thermistor have no direct contact with the solution.

Figure 3 is a schematic drawing of an embodiment of the ultrasound probe in the cuvette mode. Pair of ultrasound transducers and a thermistor are mounted on the sides of the cuvette for which it contains the fluid for measurement. In this design, the transducers and thermistor are in

1 direct contact with the solution. The housing containing the cuvette has the function of
2 maintaining temperature at a preset value.

3 Figure 4 is an illustration identifying the phase and time shift among the excitation signal,
4 that to the emitting ultrasound transducer, and that from the receiving ultrasound transducer. The
5 excitation depicted has a constant frequency. Only over a finite time (five oscillation periods are
6 depicted here and then repeated 26 cycles later), the excitation signal is passed through to excite
7 the emitting transducer to emit ultrasound. After the transmission of ultrasound through the
8 fluid, the receiving transducer picks up the ultrasound. Its amplified version is depicted here. The
9 transmission time, exemplified by the time for valley E in the emitting signal to be transmitted to
10 valley R in the receiving signal, is composed of n oscillation periods (an n of 15 is depicted) and
11 a phase shift between the excitation signal and receiving signal (ϕ).

12 Fig. 5 depicts the hardware employed to digitize the excitation signal (or the signal to the
13 emitting transducer) and the signal from the receiving transducer, the storage of the data in the
14 memory of interface processor, and then its transfer to the computer for the determination of the
15 phase shift.

16 Figure 6 is the density of saline, phase shift, and salt concentration in saline at 23°C. The
17 density is measured by a MDMS and the phase shift by an insertion ultrasound probe. No gating
18 of the excitation signal was employed for this data set. The range of density is achieved by
19 varying the salt concentration in the saline.

21 Description of the Preferred Embodiments

22 Figure 1 shows an embodiment of the ultrasound probe in the insertion mode. In this
23 embodiment, the probe 21 includes an inserting mechanism 26, which is mounted with the

ultrasound emitting transducer 22, the receiving transducer 24, and the thermistor 66. With the insertion of the probe into a fluid system such as a chemical system or pipeline, the surfaces of the transducers 22 and 24 and thermistor 66 are directly in contact with the fluid flowing there.

Transducers 22 and 24 are part of said ultrasound probe, which is attached to a signal processing unit. The signal processing unit is comprised of a function generator 20, an amplifier 68, a dual channel analog-to-digital (A/D) converter 70, an interface processor 72, and a computing mechanism 74 as shown in Figure 5. The function generator 20 transmits a power signal, preferably via a cable, to activate the emitting transducer 22 into producing a train of ultrasound wave at an appropriate frequency ($f_{\text{ultrasound}}$). One preferred frequency is about 5 Megahertz, but any frequency deemed appropriate by one skilled in the art would suffice.

This power signal is also digitized as an excitation signal by one channel of the dual channel (A/D) converter 70 within the ultrasound signal-processing unit. When the excitation frequency of the excitation signal is chosen as 5 Megahertz, the emitting transducer emits ultrasound at the frequency of 5 Megahertz. The sampling frequency of the A/D converter is chosen to be an integer multiple of the excitation frequency. This integer is designated as m . For an ultrasound/excitation frequency of 5 Megahertz and an A/D converter's sampling frequency (f_{sampling}) of 65 mega samples per second (MSPS), m is 13, meaning there are 13 digitized samples over one full ultrasound oscillation. Or, if an A/D converter with a sampling frequency of 105 MSPS is used, m will be 21. When low cost A/D converters at higher sampling frequencies become available, the ultrasound frequency or the number of samples per oscillation cycle can be increased to improve the resolution of the density/solute monitor. The receiving transducer 24 receives the ultrasound wave after its passage through the fluid. The signal is amplified by amplifier 68 and digitized through the other channel of the dual channel A/D

converter 70. Both the digitized excitation and receiving signals are sent to the interface processor 72 for storage and a computing system 74 for analysis.

The system of the present invention uses continuous measurements of phase shift and transmission time of ultrasound waves in a fluid to assess sound velocity, density, solute concentration, compressibility, and changes in these quantities. Once the ultrasound probe is inserted into a fluid and the signal processing unit described above transmits and digitizes ultrasound waves through the fluid, the computing system 74 is ready to determine phase shift and transmission time. The transmission time (T_{shift}) depicted in Fig. 4 is the time for valley E of the emitting signal after transmission in becoming valley R of the receiving signal. With the use of continuous wave, the period of each oscillation (T_0) is $1/f_{\text{ultrasound}}$. To facilitate the determination of transmission time, it is divided into two parts. The first part is composed of n periods of oscillation, which is the time for valley E to reach a valley of the excitation signal that is closest to the valley R. A peak detector and a clock determine this shift. The second part reflects the phase shift from the valley of the excitation signal to the valley R. To be determined from the procedure described next, this phase shift ϕ has the range in between -180° and 180° . Accordingly the transmission time is expressed as:

$$T_{\text{shift}} = T_0 (n + \phi/360^\circ) \quad \text{Equation 1}$$

$$\text{or} \quad = (n + \phi/360^\circ)/f_{\text{ultrasound}} \quad \text{Equation 2}$$

Let us identify the excitation and receiving samples stored on the interface processor as E_i and R_i respectively with i being the sampling index. Once some 1000 to 2000 samples from each signal are stored, the computer instructs the interface processor to transfer the data for processing. First, their average is determined and subtracted to achieve a zero average. Then the data are multiplied and summed as specified by Equation 3 and 4.

$$M_1 = \Sigma(E_i R_i) \quad \text{with the summation from } i = 1 \text{ to } N \quad \text{Equation 3}$$

$$M_2 = \Sigma(E_i R_{i+j}) \quad \text{with the same summation as above} \quad \text{Equation 4}$$

where j is chosen so that the receiving signal is shifted by about one quarter of a cycle. It is

$$j = \text{Round}(m/4) \quad \text{Equation 5}$$

The function *Round* stands for the nearest round off of a number to an integer. The total number N used for the summation is chosen to be an integer multiple of m and to cover most of the period over which we have values for the receiving signal. When the number of cycles to be covered is larger than 60, our computation results indicate good sensitivity in sound velocity determination will be achieved. With M_1 and M_2 so calculated, we determine the phase shift of the receiving signal from the emitting signal (φ) as:

$$\varphi = \tan^{-1}[M_2/(M_1 \sin \theta) - \cot \theta] \quad \text{Equation 6}$$

where φ and θ are expressed in the unit of degree and θ is $360^\circ \cdot (j \cdot f_{\text{ultrasound}}/f_{\text{sampling}})$. If m is a multiple integer of 4, then $\theta = 90^\circ$ and Equation 6 reduces to the one commonly used in phase lock computation:

$$\varphi = \tan^{-1}[M_2/M_1] \quad \text{Equation 7}$$

Two fluids typical to certain fluid processing will be used to calibrate the probe in the factory or in situ. Let the sound velocity of the two calibrating fluids be c_1 and c_2 and the corresponding phase shift be φ_1 and φ_2 . The time for the ultrasound to transmit from the emitting transducer through the fluid to the receiving transducer relates the measured phase shift by these equations:

$$(n + \varphi_1/360^\circ) T_0 = L/c_1 \quad \text{Equation 8}$$

$$(n + \varphi_2/360^\circ) T_0 = L/c_2 \quad \text{Equation 9}$$

where L is the distance between the transducers for this insertion probe. Suppose the sound velocity of the fluid designated for the measurement is c_3 and the measured phase shift is φ_3 .

Then they are related by

$$(n + \varphi_3/360^\circ) T_0 = L/c_3 \quad \text{Equation 10}$$

Equations 8, 9 and 10 can be reorganized to yield Equation 11 to determine c_3 from φ_3 :

$$c_1/c_3 = 1 - (1 - c_1/c_2)(\varphi_3 - \varphi_1)/(\varphi_2 - \varphi_1) \quad \text{Equation 11}$$

Using a series of fluid samples having a range of solute concentration, we can use the ultrasound probe and the MDMS to determine the sound velocity (c) and the density (ρ) respectively. It is known that the compressibility (κ) of the fluid relates to sound velocity and density by

$$\kappa = \rho/c^2 \quad \text{Equation 12}$$

By plotting the measurements and calculations against each other, we obtain a set of empirical equations for converting the measured sound velocity in terms of density, compressibility, or solute concentration.

For most cases in industrial and clinical application, the difference among the three sound velocities is smaller than a few percentages. Thus, we can linearize Equation 11 to relate the sound velocity to phase shift by:

$$c_3 = c_1 + (c_2 - c_1)(\varphi_3 - \varphi_1)/(\varphi_2 - \varphi_1) \quad \text{Equation 13}$$

Since the change of density is also smaller than a few percentages, the change in density and that in sound velocity can be related through a linear equation. Accordingly, Equation 13 can be converted to the following form for the determination of density:

$$\rho_3 = \rho_1 + (\rho_2 - \rho_1)(\varphi_3 - \varphi_1)/(\varphi_2 - \varphi_1) \quad \text{Equation 14}$$

where ρ_3 is the density being measured, and ρ_1 and ρ_2 the density of the calibrating fluids. In the case of protein solution, the density is linearly related to the concentration of protein C. If the fluid in the pipeline or chemical reactor also has its solute concentration linearly related to the density, we have Equation 15 to derive from the phase shift measurements the solute concentration C_3 :

$$C_3 = C_1 + (C_2 - C_1)(\varphi_3 - \varphi_1)/(\varphi_2 - \varphi_1) \quad \text{Equation 15}$$

In the special case that the solute concentration for one calibrating fluid C_1 is zero, Equation 15 is simplified to:

$$C_3 = C_2 (\varphi_3 - \varphi_1)/(\varphi_2 - \varphi_1) \quad \text{Equation 16}$$

Equation 13 is regarded as a two-constant calibration equation of the probe or probes of the monitoring system to convert phase φ_3 to c_3 . In this equation, c_1 is given and the two constants are φ_1 and $(c_2 - c_1)/(\varphi_2 - \varphi_1)$. These two constants are determined by the two fluid calibration procedure. In the same way, one can define the two constants in equation 14 or 15 for converting phase to density or solute concentration respectively.

A signal processing procedure similar to the probe calibration discussed above is applicable to the case where the emitting ultrasound is identical to the excitation signal, i.e. without the gating shown in Fig. 4. In this scheme, wave reflection will take place and the total transmission time cannot be determined. However, Equations 3, 4 and 6 can be used to determine the phase shift of the receiving ultrasound from the emitting one. With the values of φ_1 and φ_2 determined for a given ultrasound probe in the factory, one finally uses Equation 14 to 16 to determine from the phase shift measurement φ_3 the sound velocity, density, and solute concentration. This computation scheme as applied to blood, saline and plasma has been described in U.S. Patent No. 6,740,036, to which the present application claims priority. The

1 computation scheme and monitoring system can be used to determine sound velocity, density,
2 and solute concentration measurements for various fluids in industries including, but not limited
3 to, the following: paper, petroleum, chemical, pharmaceutical, food, and bioprocessing
4 industries.

5 The equations derived for the insertion probe are applicable to the cuvette mode of the
6 ultrasound solute probe as shown in Figure 3. The transducers are identified as 22 and 24. In this
7 case the cuvette 23 is housed in a controlled environment with a preset temperature.

8 The clip-on mode of the ultrasound probe depicted in Figure 2 has a trough for the
9 insertion of tubing 14. In this configuration, the transmission time from transducer 22 to
10 transducer 24 includes the transmission time through the walls of the tube. However, the
11 subtraction process employed in the derivation of Equation 11 also has the additional
12 transmission time subtracted out so that Equation 11 remains valid for the probe of clip-on mode.
13 In this embodiment, the clip 26 has a trough about 5 mm for the insertion of hemodialysis tubing
14 14 whose outside diameter is about 6.2 mm. Ultrasound gel is used to facilitate the insertion of
15 the tubing 14 into the clip and to provide an airtight contact between the tubing 14 and the
16 transducers 22, 24, preventing problems and errors that can be caused by the reflection of
17 ultrasound through air bubbles likely trapped between the transducers and tubing.

18 Pipeline, tubing, or chromatography columns with a diameter other than 6.2 mm can also
19 be used in the system and the dimensioning adjustments to the clip will be obvious to those
20 skilled in the art. The resulting adjustment to convert phase shift to density or solute
21 concentration will be incorporated through the parameters stored in a data file accompanying the
22 probe. To gain a larger receiving signal, one can employ a lower ultrasound frequency such as 1
23 Megahertz to power the emitting transducer. With the sampling frequency remaining at 65

MSPS, one will have 65 samples digitized over one period of oscillation while the total number of samples used in the determination of phase shift may remain in the range of 1000 to 2000.

When the insertion or clip-on mode of the solute monitor is mounted onto the end of a column of chromatography process to assess solute concentration, we note that the transmission time includes that through the column wall, the porous beads in the column and the fluid. The presence of the beads will alter the relation between the fluid density and phase shift, which can be resolved by the on-line calibration procedure described later.

In application, the ultrasound probe of insertion mode is inserted into a fluid processing system such as a pipeline or chemical processing system for continuous measurement of the phase shift of ultrasound transmission in the fluid. In addition, a test fluid with a density ρ_{test} at a volume ΔV is injected into the system upstream of the probe. Let the flow be Q and the volume of fluid situated between the injection and measurement site be V_1 . According to the density dilution theory, one deduces from the principle of mass conservation the relation specified in Equation 17

$$Q \int (\rho_0 - \rho) dt = \Delta V (\rho_0 - \rho_{\text{test}}) \quad \text{Equation 17}$$

where ρ is the density being measured, ρ_0 the steady state density before the injection, and the integration limit is over the time that the density is transiently deviated from the steady state density. Corrections can be made for the integration when the injected fluid re-circulates back through the probe. With most small injections, the density change from ρ_0 is small.

Equation 14 can be re-expressed as a linear relation between density change $\Delta\rho$ and the phase change $\Delta\phi$ with a calibration constant b_1 , i.e.

$$\Delta\rho = b_1 \Delta\phi \quad \text{Equation 18}$$

Its substitution into Eq. 17 yields Equation 19 for *in situ*, on-line determination of the calibration constant

$$b_1 = (\Delta V/Q)(\rho_{\text{test}} - \rho_0) / \int \Delta \varphi dt \quad \text{Equation 19}$$

Using Equation 14, one can convert Equation 17 to Equation 20:

$$Q = \Delta V(\varphi_{\text{test}} - \varphi_0) / \{ \int (\varphi - \varphi_0) dt \} \quad \text{Equation 20}$$

where ρ_0 , ρ_{test} , ρ , φ_0 , φ_{test} and φ are respectively the replacements of ρ_1 , ρ_2 , ρ_3 , φ_1 , φ_2 and φ_3 in Equation 14. Equation 20 can therefore be used for the calculation of the flow

The consideration on mean transit time, volume and flow in the density dilution theory yields Equation 21 to relate the volume and flow:

$$Q = V_1 \int (\varphi - \varphi_0) dt / \{ \int (\varphi - \varphi_0) t dt \} \quad \text{Equation 21}$$

From Equation 20 and 21, we can solve for the value of φ_{test} when the flow and volumes are known. The difference between the solute concentration in the flowing fluid and that in the test fluid can now be related to the difference between φ_{test} and φ_0 .

As another alternative to measure the flow, one can place two probes in two locations along the pipeline or chemical processing system. The flow can be calculated as:

$$Q = V_{4-5} \int (\varphi_4 - \varphi_0) dt / \{ \int (\varphi_5 - \varphi_4) t dt \} \quad \text{Equation 22}$$

where V_{4-5} is the fluid volume of the pipeline or chemical system in between the two probes, φ_4 is the phase shift measured by the upstream probe, and φ_5 that by the downstream probe.

There are several working models of the ultrasound system to assess blood density. In one signal processing embodiment the transducer 22 of Fig. 1 and 5 is activated by any commercially available pulser/receiver, including a Panametrics 5072PR pulser/receiver, to emit ultrasound impulses of about 15 to 20 Megahertz at a rate of about 100 Hertz. Each pulse contains about 4 to 6 oscillations. After its transmission through the flowing blood, the second

1 transducer 18 receives the ultrasound pulse. The trigger signal from the pulser/receiver triggers a
2 digital oscilloscope such as a LeCroy 9350AL oscilloscope or a Synatec A/D converter to sample
3 the signal from the receiver 24 at 100 Megahertz to 1 Gigahertz. Some ten digitized samples of
4 the pulse are compared by a computer for the determination of the phase shift. The sensitivity
5 achievable with this process appears at best of the order nanosecond.

6 In another embodiment, the signals from the receiving transducer and the function
7 generator, which excites the emitting transducer, are processed by a phase lock amplifier such as
8 Stanford Research System SR 844, which is powerful in processing signals with a frequency as
9 high as 200 Megahertz. Many digitized samples from the continuous ultrasound are employed
10 for the calculation. At the ultrasound frequency of interest here, the use of SR 844 provides
11 sensitivity about one order of magnitude higher than the pulse system described previously.

12 In our preferred embodiment, the ultrasound probe is used in conjunction with a novel
13 ultrasound signal processing unit, a new computation scheme, and a two-fluid calibration
14 procedure. This new scheme is an improved version of the system described in U.S. Patent No.
15 6,740,036 as we relax the requirement that the value of m in Equation 5 must be an integer
16 multiple of 4. In the current invention, the digitized data of some 100 oscillations (or 1000 to
17 2000 digitized samples) are employed. In comparison with the pulse procedure, the use of more
18 samplings for signal processing enables us to gain higher sensitivity in phase shift determination.

19 As in the SR 844 phase lock amplifier, the 90-degree shift of the excitation or receiving
20 signal in Equation 4 is accomplished by electronic means. Our scheme achieves the shift by
21 shifting the index of digitized receiving signals for multiplications and summations. Since the
22 shift in general may not be exactly 90-degree, the more general Equation 7 is deduced to carry
23 out the computation of the phase shift between the emitting and receiving signal. Our test results

1 indicate that our signal processing unit and the use of Equation 3, 4 and 6, even with a sampling
2 rate of 65 MSPS (or about 15 ns a sample), can achieve a phase resolution of the order 0.03 ns,
3 which is comparable to that via the SR844 amplifier. Only with this sensitivity, can the density
4 and solute concentration expected to occur in industrial and clinical applications be measured.

5 Because of the new algorithm and the simplicity in hardware design, our invention is in
6 the position of being built as an IC chip. The end result of the use of IC chip will be a monitor
7 with a much lower manufacturing cost than a system using SR 844 phase lock amplifier to
8 process the signals.

9 The solutes in the solution may exhibit different characteristics to absorbance or
10 reflectance at various wavelength of the light. In a preferred embodiment, the ultrasound probe
11 of the monitoring system works in conjunction with a light-emitting mechanism such an optical
12 detector or a spectrophotometer to measure the absorbance and/or reflectance of fluid in the
13 monitoring system. An optical detector preferably comprises at least one light source and filter
14 and at least two photomultipliers. The spectrophotometer preferably comprises at least one light
15 emitting diode and at least two photodiodes. Conventionally, optical modality requires the
16 detector be calibrated with solutions of different solute concentration. However, as described
17 later, one can employ the ultrasound probe and the on-line procedure to calibrate the optical
18 modality. Let us illustrate this procedure with blood as the fluid and the optical modality being
19 an IR detector. At an appropriate IR frequency, the detector has been used to assess hematocrit,
20 the volumetric percentage of red blood cells in blood.

21 In clinical practice, the monitors are mounted onto the hemodialysis circuit, which
22 withdraws blood from an artery and returns the blood after its passage of the hemodialysis
23 machine back to a vein of the patient. A bolus of isotonic saline is injected into the circuit to

flow through the hemodialysis machine and then the monitors. The sound velocity of saline is lower than that of blood. The passage of the saline after its mixing with the circulating blood will be recognized by the density monitor as a reduction in phase shift. Since there are no red blood cells in saline, we also expect to see a transient decrease in hematocrit, which will be picked up by the IR detector because of the resulting change in absorbance or reflectance characteristics of blood. Let us express the measurement of the optical detector as optical density (OD). When the blood is mixed with a saline of density ρ_s and no red blood cells, the dilution of the density (ρ_b) and hematocrit (H) of blood follow Equation 21.

$$(\rho_b - \rho_s) = [(\rho_{b,1} - \rho_s)/H_1]H \quad \text{Equation 21}$$

where $\rho_{b,1}$ is the steady-state blood density and H_1 is the steady-state hematocrit before the saline injection.

By plotting the change in optical density ΔOD against that of density $\Delta \rho_b$ as detected through the ultrasound probe, we can obtain the slope b_2 in the linear relation of Equation 22:

$$\Delta \rho_b = b_2 \Delta OD \quad \text{Equation 22}$$

Its combination with Equation 21 for saline dilution yields Equation 23:

$$\Delta H/H_1 = [b_2/(\rho_{b,1} - \rho_s)]\Delta OD \quad \text{Equation 23}$$

In practice, the optical detector is located, for example, downstream of the ultrasound probe. To carry out the data analysis through Equation 22, we will adjust the optical signal by a time for which the linear fit between the optical density and density has the correlation coefficient closest to unity. Then the slope of this linear fit is taken as b_2 . Once the slope is measured with this on-line procedure, Equation 23 is the calibration equation to convert the change in optical density to the hematocrit ratio ($\Delta H/H_1$).

1 In industrial applications, the injectate may contain a number of solutes of interest to the
2 chemical and biological process. Each solute may have different absorbance or reflectance
3 characteristics. Thus the spectrum of the optical detector will be set up to differentiate the
4 absorbance or reflectance of the solutes. Because of difference in molecular sizes or activities,
5 the passage of these solutes through the chemical system, biological reactor or chromatography
6 column may occur at various times. Their presence in the flowing fluid will alter the phase shift
7 and light absorbance as the fluid passing through the monitor. A procedure similar to hematocrit
8 calibration can be applied as an on-line means to calibrate the optical detector in industrial
9 setting. Conversely, the specificity of the optical detector in solute identification allows us to
10 pinpoint which passage detected by the ultrasound probe is associated with which specific solute.

11 The passage of solute as detected by the ultrasound probe can now be used to activate a
12 fractional collector to collect the solution containing most of the specific solute. This on-line
13 control will reduce the collection of other solutes coming through the probe at other times and to
14 improve the purity of the specific solute in the collection. This characteristic to identify the
15 presence of solutes through the use of density/solute monitor can also be used to improve the
16 collection of solution containing no solutes for reuse by the chromatography process.

17 γ ray is absorbed by the fluid over its passage. The attenuation of γ ray, a physical
18 characteristic of the fluid, can be associated with and thus be used to determine the density of the
19 fluid. The combination of this attenuation with the ultrasound characteristics may further
20 enhance our ability to differentiate the kind of fluid flowing pass the density/solute monitor.

21 Infusion of hypertonic saline has been used clinically to extract fluid from the tissue in
22 human body to the circulation. The extracted fluid has a density lower than the blood. Thus its
23 mixing with blood will lower the density of blood. Consequently, multi-modality monitor on

conductivity and phase shift may allow us to assess the process of fluid extraction from the tissue.

Tracers have been used to monitor dynamic events occurring in a chemical system, pipeline, or the human circulation system. Some tracers can be detected by magnetic resonance imaging (MRI) system or CT scan. If the tracers are in the form of vesicles containing a fluid or other medium that its density is different from that of the flowing fluid, then the density or compressibility of fluid may be altered by the presence of tracers and be detected by the density monitor. The tracer can be a substance tagged with radioactive element or dye. Radioactivity counter can detect the former and optical detector set at the frequency most sensitive to the dye can detect the latter. The use of multi-modality detection systems and tracers may further improve the sensitivity and specificity of the density/solute monitor to better track the movement of solutes through chemical processing system or human circulation.